Scarica l'app Stockscreener
7.43
17.75%
1.12
Dopo l'orario di chiusura:
7.17
-0.26
-3.50%
Precedente Chiudi:
$6.31
Aprire:
$6.22
Volume 24 ore:
163.16K
Relative Volume:
1.39
Capitalizzazione di mercato:
$138.59M
Reddito:
-
Utile/perdita netta:
$-22.38M
Rapporto P/E:
-4.7935
EPS:
-1.55
Flusso di cassa netto:
$-15.54M
1 W Prestazione:
-5.59%
1M Prestazione:
+21.80%
6M Prestazione:
-8.72%
1 anno Prestazione:
-22.28%
Intervallo 1D:
$6.00
$7.48
Intervallo di 1 settimana:
$6.00
$8.2399
Portata 52W:
$5.85
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Trend Tracker for (NVCT) - Stock Traders Daily
Nuvectis Pharma's NXP900 Shows Promise in NSCLC Treatment, NXP800 Data Update Anticipated - Vancity Buzz
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - StockTitan
NVCTNuvectis Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
Learn to Evaluate (NVCT) using the Charts - Stock Traders Daily
Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance
(NVCT) Trading Advice - Stock Traders Daily
Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR
A new trading data show Nuvalent Inc (NUVL) is showing positive returns. - SETE News
What's Going On With Nuvve Stock? - Benzinga
Rhumbline Advisers Has $3.18 Million Position in NVE Co. (NASDAQ:NVEC) - Defense World
ESMO where that came from: Nuvalent bags $500M on hot early data - BioWorld Online
SEC Form 424B5 filed by Nuvalent Inc. - Quantisnow
Why Nuvalent (NUVL) Shares Are Down 6% Today - Benzinga
Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation (NASDAQ:NUVL) - Seeking Alpha
Nuvalent Inc Inc. (NUVL) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Biopharma co Nuvalent slips after upsized $500 mln stock offering priced - XM
Nuvalent 5M share Secondary priced at $100.00 - TipRanks
Nuvalent announces pricing of $500M upsized stock offering - MSN
Nuvalent Earns Relative Strength Rating Upgrade - Investor's Business Daily
Nuvoco Vistas Corporation Block Deal | 1.2% equity worth ₹158 crore changes hands - CNBCTV18
Nuvalent (NASDAQ:NUVL) Reaches New 1-Year High Following Analyst Upgrade - Defense World
Nuvoco Vistas sees large block trade: 45 lakh shares worth ₹158 crore - Business Upturn
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock - PR Newswire
Nuvalent stock outlook positive amid key questions on trial enrollment and FDA approval strategy - Investing.com India
Nuvectis Pharma’s NXP900 Shows Promise in NSCLC Treatment, New Report Suggests - Vancity Buzz
Monitoring Nuvalent Inc (NUVL) after recent insider movements - Knox Daily
An analyst sees good growth prospects for Nuvation Bio Inc (NUVB) - SETE News
Company’s Banking Shares: Up -97.40% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Nuvalent gains after brokerages raise PT on promising cancer therapy data - XM
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch - BioSpace
Nuvalent Shares Gain on Cancer Drug Trial Updates - MarketWatch
Nuvalent price target raised to $132 from $102 at BMO Capital - TipRanks
Nuvalent announces $350M offering of Class A common stock - TipRanks
Nuvalent Announces Public Offering of Common Stock - Yahoo Finance
NUVVE ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT - Nasdaq
Nuvalent (NASDAQ:NUVL) Stock Price Down 3.9% on Insider Selling - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 8.5% - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5% - Defense World
Nuvectis’ NXP800 gains FDA ODD for cancer treatment - MSN
Insider Buyers Lose Additional US$46k As Nuvectis Pharma Dips To US$115m - Simply Wall St
When (NVCT) Moves Investors should Listen - Stock Traders Daily
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Nuvectis Pharma Inc (NVCT) Becoming More Attractive for Investors - Knox Daily
Is Nuvectis Pharma Inc (NVCT) worth investing in despite its overvalued state? - US Post News
The time has not yet come to remove your chips from the table: Nuvectis Pharma Inc (NVCT) - SETE News
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvectis Pharma Inc Azioni (NVCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
May 10 '24 |
Buy |
6.40 |
2,000 |
12,800 |
3,244,484 |
| Poradosu Enrique | Chief Science & Business Off |
May 10 '24 |
Buy |
6.29 |
500 |
3,145 |
1,504,319 |
| Shemesh Shay | Chief Dev. & Ops. Officer |
May 10 '24 |
Buy |
6.32 |
1,113 |
7,034 |
1,493,068 |
| BENTSUR RON | Chairman & CEO |
Mar 18 '24 |
Buy |
10.29 |
5,000 |
51,450 |
3,242,484 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):